Cargando…
Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication; however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of cor...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915418/ https://www.ncbi.nlm.nih.gov/pubmed/31703332 http://dx.doi.org/10.3390/medicina55110729 |
_version_ | 1783480011391500288 |
---|---|
author | Yoon, Hyeon Jeong Woo, Je Moon Ji, Yong Sok Yoon, Kyung Chul |
author_facet | Yoon, Hyeon Jeong Woo, Je Moon Ji, Yong Sok Yoon, Kyung Chul |
author_sort | Yoon, Hyeon Jeong |
collection | PubMed |
description | Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication; however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of corneal neovascularization (CNV). Materials and Methods: Murine CNV was induced by means of total de-epithelization and alkali burn. Mice were divided into five groups according to topical treatment: untreated control, phosphate-buffered saline (PBS), 0.1% and 0.5% rivoceranib, and 0.5% bevacizumab. CNV area and index were measured 7 and 14 days after treatment. After corneal tissues were excised at day 14, the blood and lymphatic vessels were quantified by cluster of differentiation 31 (CD31) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) immunofluorescence, respectively. Results: After 14 days, treatment groups with 0.1% and 0.5% rivoceranib and 0.5% bevacizumab showed a decrease in CNV area and index compared with the untreated and PBS groups (all p < 0.01). Blood and lymphatic vascularization significantly decreased in the 0.5% rivoceranib and 0.5% bevacizumab groups, as measured by CD31 and LYVE1 immunofluorescence. There was no significant difference of vascularization between the 0.5% rivoceranib and bevacizumab groups. Conclusions: Topical application of rivoceranib could effectively decrease CNV equivalent to topical bevacizumab in a murine model. |
format | Online Article Text |
id | pubmed-6915418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69154182019-12-24 Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization Yoon, Hyeon Jeong Woo, Je Moon Ji, Yong Sok Yoon, Kyung Chul Medicina (Kaunas) Article Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication; however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of corneal neovascularization (CNV). Materials and Methods: Murine CNV was induced by means of total de-epithelization and alkali burn. Mice were divided into five groups according to topical treatment: untreated control, phosphate-buffered saline (PBS), 0.1% and 0.5% rivoceranib, and 0.5% bevacizumab. CNV area and index were measured 7 and 14 days after treatment. After corneal tissues were excised at day 14, the blood and lymphatic vessels were quantified by cluster of differentiation 31 (CD31) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) immunofluorescence, respectively. Results: After 14 days, treatment groups with 0.1% and 0.5% rivoceranib and 0.5% bevacizumab showed a decrease in CNV area and index compared with the untreated and PBS groups (all p < 0.01). Blood and lymphatic vascularization significantly decreased in the 0.5% rivoceranib and 0.5% bevacizumab groups, as measured by CD31 and LYVE1 immunofluorescence. There was no significant difference of vascularization between the 0.5% rivoceranib and bevacizumab groups. Conclusions: Topical application of rivoceranib could effectively decrease CNV equivalent to topical bevacizumab in a murine model. MDPI 2019-11-07 /pmc/articles/PMC6915418/ /pubmed/31703332 http://dx.doi.org/10.3390/medicina55110729 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yoon, Hyeon Jeong Woo, Je Moon Ji, Yong Sok Yoon, Kyung Chul Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization |
title | Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization |
title_full | Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization |
title_fullStr | Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization |
title_full_unstemmed | Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization |
title_short | Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization |
title_sort | comparison of the therapeutic efficacies of topical rivoceranib and topical bevacizumab in a murine model of corneal neovascularization |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915418/ https://www.ncbi.nlm.nih.gov/pubmed/31703332 http://dx.doi.org/10.3390/medicina55110729 |
work_keys_str_mv | AT yoonhyeonjeong comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization AT woojemoon comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization AT jiyongsok comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization AT yoonkyungchul comparisonofthetherapeuticefficaciesoftopicalrivoceranibandtopicalbevacizumabinamurinemodelofcornealneovascularization |